LSP et al. back $38.5m series-B for DNA Script

New investors LSP and BPI France, and existing investors Illumina Ventures, M Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners all took part in the round.

BPI France has invested via its Large Venture fund, closed in €600m in 2013.

The proceeds will enable DNA Script to accelerate the development of its enzymatic technology and nucleotide chemistry platform, and deliver the promise of same-day results. The company is also recruiting in the US for its product development and commercialisation teams in preparation for product launch, as well as expanding its Paris-based research team.

Previous funding
The series-A round in 2017 saw existing investors Sofinnova, Kurma and Idinvest, and new backers Illumina Ventures and Merck Ventures, invest €11m in the business. The funds raised were meant to allow DNA Script to strengthen its enzymatic technology and nucleotide chemistry platform in order to manufacture oligonucleotides in a faster, cleaner and more affordable way compared with current market standards.

Company
Founded in 2014 in Paris, DNA Script's technology allows the production of synthetic DNA via the use of proprietary template-free enzymatic technology.

The technology, now reliable enough for its first commercial applications, has the potential to accelerate the development of new therapeutics, enhanced diagnostics, sustainable chemical production, improved crops, and DNA data storage, according to a statement by the investors.

People
DNA Script – Thomas Ybert (CEO, co-founder).
Life Sciences Partners – Joachim Rothe (managing partner).
Sofinnova Partners – Joško Bobanović (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• IDInvest Partners (AGF Private Equity)
• BPI France
• Sofinnova Partners